Morningside North, 170 W Oak St, Chicago, IL 60610, US

ExoMira Medicine, based in Chicago, IL, is a pioneering biotech company focused on developing innovative immunotherapies for cancer, viral infections, and other diseases. Their mission is to create targeted pipelines for immunotherapy through the use of investigator new drugs (IND) for clinical trials, with a particular emphasis on exotic cancer immunotherapies. Their flagship product, USP22 inhibitors, along with human therapeutic antibodies and next-generation exosome biologics, form the foundation of their multi-line approach to combatting diseases. With a strong emphasis on research and development, ExoMira Medicine is dedicated to strategizing immunotherapeutic small compounds, developing human antibodies, and engineering anti-cancer and anti-viral exosomes. Their cutting-edge technologies, such as artificial intelligence-guided screening and redesign, aim to target solid tumor cells, regulatory T cells, circulating tumor stem cells, and primary tumors and metastases. Through their groundbreaking work, ExoMira Medicine is at the forefront of advancing the field of immunotherapy and making significant contributions to the fight against cancer and viral infections.Generated from the website